Every Form 4 that SELECT MEDICAL HOLDINGS CORP (SEM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SEM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SEM filings page.
Select Medical Holdings director Thomas Scully disposed of his remaining shares as part of a cash merger. The Form 4 shows a disposition of 103,424 shares of common stock to the issuer at $16.50 per share, leaving him with zero shares directly held after the transaction.
According to the merger agreement, each share of common stock, including unvested restricted shares that vested immediately before closing, was converted into the right to receive $16.50 in cash, less applicable tax withholdings. This reflects the automatic cash-out of his equity in connection with the completed merger.
Select Medical Holdings Corp director Katherine R. Davisson disposed of 60,035 shares of common stock at $16.50 per share in connection with a merger. Under the merger agreement, each of her shares, including previously unvested restricted shares that vested immediately before closing, was converted into the right to receive cash, leaving her with no remaining shares.
Select Medical Holdings director William H. Frist disposed of 306,266 shares of common stock in connection with the company’s merger. Each share was converted into the right to receive $16.50 in cash, and his direct common stock holdings fell to zero shares.
The transaction also covered unvested restricted shares, which fully vested immediately before the merger and were converted into the same cash consideration, subject to tax withholding.
SELECT MEDICAL HOLDINGS CORP director Marilyn B. Tavenner disposed of 36,035 shares of common stock in connection with a cash merger. Each share, including previously unvested restricted shares that vested immediately before closing, was converted into the right to receive $16.50 in cash. Following this merger-related conversion, she holds no shares directly.
Select Medical Holdings Corp director Thomas Daniel disposed of his remaining common stock in connection with the company’s merger. On the merger’s effective date, 80,035 shares of common stock were surrendered to the issuer at $16.50 per share, leaving him with no shares reported after the transaction.
Under the Agreement and Plan of Merger, each of his outstanding shares, including previously unvested restricted shares that fully vested immediately before closing, was converted into the right to receive cash merger consideration of $16.50 per share, less applicable tax withholdings.
Khanuja Parvinderjit S. reported disposition transactions in this Form 4 filing.
SELECT MEDICAL HOLDINGS CORP director Parvinderjit S. Khanuja had all of his common shares cashed out in a merger-related transaction. A total of 79,124 shares of common stock, including previously unvested restricted shares, were converted into the right to receive $16.50 per share in cash at the merger effective time, leaving him with no remaining shares.
Select Medical Holdings Corp director James S. Ely III disposed of 161,674 shares of common stock in connection with the company’s merger. At the effective time of the merger, each share, including previously unvested restricted shares, was converted into the right to receive $16.50 in cash per share, leaving him with no remaining shares.
Select Medical Holdings Corp executive vice president John F. Duggan reported a restructuring of 194,710 shares of common stock linked to a merger. The Form 4 shows his direct holdings in issuer common stock fell to 0 shares after the transaction.
Footnotes explain that immediately prior to the merger’s effective time, he contributed 78,043 common shares and 116,667 restricted shares to Stallion Intermediate Corporation in exchange for equivalent Parent Common Shares and restricted shares, which were then exchanged for equivalent interests in Stallion Group Parent, LP. This reflects a merger-related equity rollover rather than an open-market trade.
Select Medical Holdings executive John Tyler Hollenbach reported a merger-related restructuring of 135,084 common shares. The Form 4 notes these securities were disposed of under an Agreement and Plan of Merger involving Select Medical, Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Immediately before the merger’s effective time, Hollenbach contributed 31,751 common shares and 103,333 restricted shares to Stallion Intermediate Corporation. In return, he received an equivalent amount of Parent common and restricted shares, which were then exchanged for equivalent interests in Stallion Group Parent, LP. Following this restructuring, the Form 4 shows zero Select Medical common shares held directly in this reporting line.
Select Medical Holdings Corp vice chairman David S. Chernow reported merger-related changes in his common stock holdings. A block of 656,823 shares of common stock was converted into the right to receive $16.50 per share in cash as merger consideration.
Immediately before the merger, Chernow contributed 100,000 restricted shares to Stallion Intermediate Corporation in exchange for equivalent restricted shares of Parent, which were then exchanged for interests in Stallion Group Parent, LP. Separately, 113,421 shares were surrendered to satisfy tax withholding obligations tied to restricted stock vesting. Following these transactions, the filing shows no remaining direct holdings of the issuer’s common stock.
SELECT MEDICAL HOLDINGS CORP senior vice president Christopher Weigl reported merger-related changes in his SEM share holdings. His Form 4 shows 12,382 shares of common stock converted into the right to receive $16.50 per share in cash in connection with a merger, plus 1,872 shares surrendered to cover tax withholding on vested restricted stock.
Separately, he contributed 40,000 restricted shares to the merger parent entity in exchange for equivalent interests in Stallion Group Parent, LP. After these transactions, he directly holds 14,524 shares of SELECT MEDICAL common stock. The filing reflects merger consideration, tax withholding, and restructuring steps rather than open-market buying or selling.
Select Medical Holdings Corp’s chief financial officer, Michael F. Malatesta, reported an internal restructuring of 238,057 shares of common stock under a previously signed merger agreement. These securities were contributed to Stallion Intermediate Corporation and converted into equivalent interests in Stallion Group Parent, LP, rather than sold on the open market.
Immediately before the merger’s effective time, Malatesta contributed 79,723 common shares and 158,334 restricted shares to the merger parent entity in exchange for equivalent parent common and restricted shares, which were then exchanged for partnership interests. Following this transaction, his directly held Select Medical common stock position in the issuer was reduced to zero as part of the merger structure.
SELECT MEDICAL HOLDINGS CORP executive vice president Brian R. Rusignuolo reported a restructuring transaction involving 361,370 shares of common stock. The Form 4 shows this was an “other” type of transaction tied to a previously signed merger agreement with Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Immediately before the merger’s effective time, he contributed 203,037 common shares and 158,333 restricted shares to the merger parent in exchange for equivalent parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. After these steps, the filing reports he directly holds 0 shares of SELECT MEDICAL common stock.
SELECT MEDICAL HOLDINGS CORP’s chief executive officer, Thomas P. Mullin, reported an internal restructuring of 391,709 shares of Common Stock under a previously signed merger agreement. This was not an open‑market trade and carried a reported price of $0.00 per share.
Footnotes explain that immediately before the merger became effective, Mullin contributed 175,042 common shares and 216,667 restricted shares of Select Medical to Stallion Intermediate Corporation, the merger parent. In exchange, he received an equivalent number of parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP.
After this restructuring, the Form 4 shows 0 shares of Select Medical Common Stock held directly by Mullin, with his economic interest shifted into the new parent structure created for the merger.
SELECT MEDICAL HOLDINGS CORP president John A. Saich reported an internal restructuring of his equity stake tied to a merger transaction. The filing shows 736,412 common shares were disposed of at a stated price of $0.00 per share under an Agreement and Plan of Merger with Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Immediately before the merger’s effective time, Saich contributed 519,745 common shares and 216,667 restricted shares to Stallion Intermediate Corporation in exchange for equivalent Parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. Following this restructuring, the Form 4 reports zero shares of SELECT MEDICAL HOLDINGS CORP common stock held directly.
SELECT MEDICAL HOLDINGS CORP executive vice president Martin F. Jackson reported restructuring his holdings in connection with a merger. On the reported date, he contributed a total of 1,393,957 shares of Select Medical common stock, including indirect holdings by his son and daughter, to Stallion Intermediate Corporation (Parent) under an Agreement and Plan of Merger.
According to the footnotes, 1,138,754 common shares and 244,667 restricted shares were exchanged for equivalent Parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. Additional blocks of 2,634 common shares were similarly contributed. The filing notes that Jackson beneficially owns the indirectly held securities but disclaims beneficial ownership except to the extent of his pecuniary interest. These are non-market, merger-related conversions rather than open‑market buying or selling.
ORTENZIO ROBERT A reported disposition transactions in this Form 4 filing.
Select Medical Holdings Corp insider transactions show restructuring around a merger closing. Executive Chairman Robert A. Ortenzio and related trusts moved large holdings of common stock into the new ownership structure and partially cashed out shares.
Immediately before the merger, Ortenzio contributed 6,674,010 common shares and 407,778 restricted shares to Stallion Intermediate Corporation (Parent) in exchange for equivalent Parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. The Robert A. Ortenzio Descendants Trust similarly rolled over 1,000,000 common shares into Parent and then into Stallion Group Parent, LP, while 279,000 shares held by that trust were converted at the merger into the right to receive $16.50 per share in cash. Three separate 2014 trusts for Madeline, Kevin, and Bryan Ortenzio each contributed 280,415 common shares to Parent, also receiving equivalent Parent shares and then interests in Stallion Group Parent, LP. The filing notes that Ortenzio beneficially owns these securities indirectly and disclaims beneficial ownership beyond his pecuniary interest.
Select Medical Holdings director Russell L. Carson reported an internal restructuring of 610,035 shares of Common Stock in connection with a merger involving Stallion Intermediate Corporation and Stallion MergerSub Corporation. The shares, including 14,035 restricted shares that vested immediately before the merger, were contributed to the new parent entity. In return, Carson received an equivalent number of parent common shares, which were then exchanged for interests in Stallion Group Parent, LP. Following these transactions, the filing shows he held 0 shares of Select Medical Common Stock directly, indicating a shift from direct company ownership to ownership through the post-merger parent structure rather than an open-market trade.
Breighner Robert G. JR reported disposition transactions in this Form 4 filing.
Select Medical senior vice president Robert G. Breighner Jr. reported transactions tied to the company’s merger with Stallion Intermediate Corporation and Stallion MergerSub Corporation. At the merger’s effective time, 18,362 shares of Select Medical common stock were converted into the right to receive $16.50 per share in cash, eliminating his direct holdings.
Immediately before the merger became effective, he contributed 16,334 restricted “Rollover Shares” to the parent entity in exchange for equivalent parent common shares and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. The filing also notes that his remaining company restricted shares vested and were converted into the same cash merger consideration.
Select Medical Holdings Corp senior vice president Robert G. Breighner Jr. reported a tax-related share disposition. On the vesting of restricted stock, he surrendered 1,330 shares of common stock to satisfy his tax withholding obligation at $16.44 per share. After this non-market transaction, he directly holds 34,696 shares of Select Medical common stock.
Select Medical Holdings Corp vice chairman David S. Chernow surrendered 22,586 shares of Common Stock on April 30, 2026 to satisfy a tax withholding obligation tied to vesting of restricted stock. The shares were valued at $16.41 per share, and he now directly holds 870,244 shares.
Frist William H. reported acquisition or exercise transactions in this Form 4 filing.
Select Medical Holdings director William H. Frist received a grant of 1,094 shares of Common Stock on April 28, 2026. The shares are restricted stock issued under the Select Medical Holdings Corporation 2020 Equity Incentive Plan in lieu of a quarterly cash retainer of $18,000.
Each share in the grant was valued at $16.45, and following this award Frist directly holds 306,266 shares of Select Medical Holdings Common Stock. This is a compensation-related equity grant rather than an open-market stock purchase.
Select Medical Holdings Corporation director William H. Frist reported receiving a grant of restricted common stock as part of his board compensation. On 02/11/2026, he acquired 1,109 shares at $16.23 per share under the company’s 2020 Equity Incentive Plan, issued in lieu of a quarterly cash retainer of $18,000. Following this award, he beneficially owned 305,172 shares of Select Medical common stock, held directly.
Select Medical Holdings (SEM): Executive Vice President John F. Duggan reported a Form 4 transaction on 11/01/2025. He surrendered 4,865 shares of common stock at $13.83 under code F to satisfy tax withholding related to the vesting of restricted stock.
Following this administrative withholding, he directly owns 194,710 shares. This filing reflects a tax-related share withholding rather than an open-market sale.
Select Medical Holdings (SEM) reported an insider transaction by its Chief Financial Officer. On 11/01/2025, the CFO executed a Code F transaction, surrendering 7,357 shares of common stock at $13.83 per share to cover tax withholding tied to the vesting of restricted stock.
Following this tax-related withholding, the CFO beneficially owns 238,057 shares on a direct basis. This filing reflects administrative share withholding rather than an open‑market sale.
Select Medical Holdings (SEM) reported an insider equity award. An Executive Vice President acquired 50,000 shares of common stock on 10/28/2025 at $0 per share, recorded as a grant of restricted stock. Following the transaction, the officer beneficially owns 199,575 shares, held directly.
The restricted stock, subject to certain exceptions, will vest in full on 10/28/2029, the fourth anniversary of the grant date.
Select Medical Holdings (SEM) reported an insider equity transaction. A director received 1,266 shares of common stock on 10/28/2025 at a price of $14.22 per share. Following the grant, the reporting person beneficially owned 304,063 shares, held directly.
The filing states this was a restricted stock grant under the 2020 Equity Incentive Plan, issued in lieu of a quarterly cash retainer of $18,000. This reflects routine director compensation in stock rather than cash.
Select Medical Holdings (SEM) reported an insider equity award. The company’s Chief Accounting Officer received a grant of 20,000 shares of restricted stock on 10/28/2025 at $0 per share. According to the terms, the award will vest in full on October 28, 2029. Following the grant, the reporting person beneficially owns 54,254 shares, held directly.